Skip to search formSkip to main contentSkip to account menu

reparixin

Known as: (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide, Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-N- (methylsulfonyl)- (alphaR)-, Repertaxin 
An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Locoregional recurrence of oral squamous cell carcinoma (OSCC) dramatically reduces patient survival. Further, as many OSCC… 
2018
2018
Interleukin‐8 mediates neutrophil‐endothelial interactions in pig‐to‐human xenogeneic models
Human neutrophils are sequestered by pig lung xenografts within minutes during ex vivo perfusion. This phenomenon is not… 
2018
2018
Conserved structure and function of chemokine CXCL8 between Chinese tree shrews and humans.
2016
2016
Reparixin attenuates neuronal injury in experimental Klebsiella pneumoniae meningoencephalitis through dual effects on neuroprotection and neuroinflammation
Bacterial meningitis causes high mortality and brain damage. The host immune response is associated with brain injury. Chemokine… 
2015
2015
Abstract P6-03-01: A phase Ib study of the CXCR1/2 inhibitor reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer – First analysis
Background . Experimental models and retrospective clinical observations point to cancer stem cells (CSCs) as the culprits for… 
2013
2013
Abstract OT2-6-03: A single arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for…
Background. Experimental models and retrospective clinical observations point to Cancer Stem Cells (CSC) as responsible for tumor… 
Review
2012
Review
2012
Abstract OT2-3-01: Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC)
Background: Breast cancer stem cells (BCSCs) have the ability to self renew and generate the full range of cells that make up a… 
2008
2008
406: Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen Versus Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation
2007
2007
Pharmacological Characterization of Sch 527123 , a Potent Allosteric CXCR 1 / CXCR 2 Antagonist
In neutrophils, growth-related protein(CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants (Cytokine 14:27– 36, 2001… 
2006
2006
Neutrophil recruitment in immunized mice depends on MIP-2 inducing the sequential release of MIP-1alpha, TNF-alpha and LTB(4).
Neutrophils are thought to play an important role in the tissue damage observed in various autoimmune diseases. Chemokines… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)